Q1 Earnings Forecast for Incyte Issued By William Blair

Incyte Co. (NASDAQ:INCY) – Research analysts at William Blair issued their Q1 2025 EPS estimates for Incyte in a report released on Monday, February 10th. William Blair analyst M. Phipps expects that the biopharmaceutical company will post earnings of $0.66 per share for the quarter. William Blair has a “Outperform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $0.35 per share. William Blair also issued estimates for Incyte’s Q2 2025 earnings at $1.06 EPS, Q3 2025 earnings at $1.22 EPS and Q4 2025 earnings at $1.24 EPS.

Incyte (NASDAQ:INCY) last posted its quarterly earnings data on Monday, February 10th. The biopharmaceutical company reported $1.09 EPS for the quarter, missing the consensus estimate of $1.57 by ($0.48). Incyte had a net margin of 0.80% and a negative return on equity of 0.63%.

A number of other equities research analysts have also recently issued reports on INCY. Royal Bank of Canada lowered their price objective on Incyte from $70.00 to $68.00 and set a “sector perform” rating on the stock in a research note on Tuesday. UBS Group assumed coverage on shares of Incyte in a research report on Tuesday, December 17th. They issued a “neutral” rating and a $77.00 price target on the stock. Stifel Nicolaus raised their price objective on shares of Incyte from $75.00 to $77.00 and gave the stock a “hold” rating in a report on Monday. StockNews.com cut shares of Incyte from a “strong-buy” rating to a “buy” rating in a report on Wednesday. Finally, Morgan Stanley increased their target price on Incyte from $64.00 to $69.00 and gave the stock an “equal weight” rating in a research report on Wednesday, October 30th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $75.59.

Incyte Stock Up 4.1 %

Shares of NASDAQ INCY opened at $69.05 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.87 and a quick ratio of 1.82. The stock has a market capitalization of $13.30 billion, a PE ratio of 493.25, a P/E/G ratio of 0.53 and a beta of 0.70. Incyte has a one year low of $50.35 and a one year high of $83.95. The business’s fifty day moving average price is $71.47 and its 200-day moving average price is $69.16.

Hedge Funds Weigh In On Incyte

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Point72 Asset Management L.P. purchased a new position in Incyte during the 3rd quarter valued at $156,611,000. Mizuho Securities USA LLC boosted its stake in shares of Incyte by 13,814.7% during the 3rd quarter. Mizuho Securities USA LLC now owns 2,000,100 shares of the biopharmaceutical company’s stock valued at $132,207,000 after purchasing an additional 1,985,726 shares in the last quarter. Norges Bank bought a new stake in shares of Incyte during the 4th quarter valued at about $121,890,000. Sound Shore Management Inc. CT raised its stake in Incyte by 98.4% in the fourth quarter. Sound Shore Management Inc. CT now owns 1,201,089 shares of the biopharmaceutical company’s stock worth $82,959,000 after buying an additional 595,741 shares in the last quarter. Finally, Pictet Asset Management Holding SA raised its position in shares of Incyte by 73.4% in the 4th quarter. Pictet Asset Management Holding SA now owns 1,313,873 shares of the biopharmaceutical company’s stock worth $90,749,000 after acquiring an additional 556,218 shares in the last quarter. Institutional investors own 96.97% of the company’s stock.

Insider Activity

In other Incyte news, EVP Steven H. Stein sold 12,352 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $72.69, for a total transaction of $897,866.88. Following the completion of the sale, the executive vice president now owns 66,967 shares of the company’s stock, valued at $4,867,831.23. This represents a 15.57 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Vijay K. Iyengar sold 6,043 shares of the stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $75.38, for a total transaction of $455,521.34. Following the sale, the executive vice president now owns 30,658 shares of the company’s stock, valued at approximately $2,311,000.04. This represents a 16.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 19,695 shares of company stock valued at $1,444,356. 17.60% of the stock is currently owned by company insiders.

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.